Weight ManagementAlso known as: Adlyxin, Lyxumia, AVE0010

Lixisenatide

Lixisenatide (Adlyxin) is a highly modified, ultra-fast-acting once-daily GLP-1 receptor agonist. Built aggressively upon the Exendin-4 backbone, it is specifically weaponized against post-prandial (post-meal) blood sugar spikes. Often fused directly with long-acting basal insulin (as Soliqua), it provides an intense, localized burst of glycemic control exactly when the body is overwhelmed by a heavy carbohydrate load.

Reviewed by CalcMyPeptide Editorial Team

·Last updated: April 2026·Evidence: Strong·1 peer-reviewed citation

Quick Stats

Half-Life~3 hours

Dose Range10-20 mcg/day

Frequency1× daily

Vial Sizes0.05 mg, 0.1 mg

Bioavailability~100% (SC)

Year Developed2016

Scientific Data

Molecular Formula

C215H347N61O65S

Molecular Weight

4858.5 g/mol

CAS Number

320367-13-3

Developer

Sanofi

Mechanism of Action

Lixisenatide (Adlyxin® / Lyxumia®) is a once-daily GLP-1 receptor agonist derived from exendin-4 with 6 C-terminal lysine additions that extend its half-life vs native exenatide. It is approved for type 2 diabetes as an adjunct to basal insulin, making it particularly useful in combination with insulin glargine (as Soliqua® / Suliqua®). Its strongest action is on postprandial glucose — it slows gastric emptying aggressively, reducing meal-time glucose spikes more than other GLP-1 agents. Weight loss is modest (~2 kg vs semaglutide's 15-17%).

Source: PMID: 23404299 (GetGoal trials)

Dosing Protocol

Typical Dose	10-20 mcg/day
Frequency	1× daily
Half-Life	~3 hours
Common Vial Sizes	0.05 mg, 0.1 mg

Dosing Protocols

Starting

Dose

10 mcg

Frequency

Once daily (SC, 1 hour before first meal)

Note: 10 mcg for 14 days, then increase to 20 mcg maintenance.

Maintenance

Dose

20 mcg

Frequency

Once daily (SC)

Note: Same time each day, always before the same meal.

Administration

Route

Subcutaneous injection (abdomen, thigh, or upper arm)

Timing

1 hour before first meal of the day. Same time daily.

Fasting Required?

No — food timing not critical

Expected Timeline

Weeks 1-2

Significant postprandial glucose reduction. Mild nausea during escalation.

Months 2-6

HbA1c reduction ~0.8%. Modest weight loss 1-2 kg.

Who Is It For?

T2D with Basal Insulin

High

FDA-approved. Combination with basal insulin (Soliqua) provides complementary coverage: basal handles fasting glucose, lixisenatide handles postprandial spikes.

Postprandial Glucose Control

High

Strongest gastric emptying delay of any GLP-1 — maximizes postprandial glucose reduction.

Safety & Considerations

FDA-approved (Adlyxin). Same class warnings as all GLP-1s: MTC/MEN 2 contraindication, pancreatitis risk. Hypoglycemia risk when combined with insulin or sulfonylureas — reduce insulin dose when starting.

Regulatory & Legal Status

FDA Status (US)

Research Only

WADA Status (2026)

Not Listed

Not currently on the WADA 2026 Prohibited List. Policies may change — verify before competition.

Classification

Research Chemical

US Compounding: Not eligible / not available

⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.

Dosing Quick Reference

Lixisenatide— Dosing Guide

Dose Range

10-20 mcg/day

Half-Life

~3 hours

Frequency

1× daily

Route

Oral

0.05 mg vial0.1 mg vial

Weight Managementcalcmypeptide.com

Frequently Asked Questions

What makes lixisenatide different from semaglutide?▼

Lixisenatide is once-daily with the strongest postprandial glucose reduction but modest weight loss. Semaglutide is once-weekly with dramatically superior weight loss (15-17%). Lixisenatide is most valued as a basal insulin companion drug (Soliqua).

Can lixisenatide be used with insulin?▼

Yes — it is specifically designed for this. Soliqua 100/33 combines insulin glargine U-100 with lixisenatide 33 mcg in a single pen, simplifying type 2 diabetes management.

References

Riddle MC et al. “"Lixisenatide as add-on to basal insulin in T2D (GetGoal-L)".” Diabetes Care (2013). PMID: 23150280

📚 Related Articles

GLP-1 Dose Escalation Guide: Semaglutide, Tirzepatide & Retatrutide

14 min read • Pillar Guide

Looking for a trusted source? See our recommended suppliers →

Independently tested · COA-verified · Save 10% with our exclusive code

← Back to Peptide Library